Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 851983-85-2, Tok-001, Vn/124-1, Galaterone, Tok 001, Vn/124

Molecular Formula

C₂₆H₃₂N₂O

Molecular Weight

388.5 g/mol

InChI Key

PAFKTGFSEFKSQG-PAASFTFBSA-N

FDA UNII

WA33E149SW

Galeterone is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.

1 2D Structure

Galeterone

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

2.1.2 InChI

InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1

2.1.3 InChI Key

PAFKTGFSEFKSQG-PAASFTFBSA-N

2.1.4 Canonical SMILES

CC12CCC(CC1=CCC3C2CCC4(C3CC=C4N5C=NC6=CC=CC=C65)C)O

2.1.5 Isomeric SMILES

C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O

2.2 Other Identifiers

2.2.1 UNII

WA33E149SW

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3beta-ol

2. 3-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene

3. Vn-124-1

2.3.2 Depositor-Supplied Synonyms

1. 851983-85-2

2. Tok-001

3. Vn/124-1

4. Galaterone

5. Tok 001

6. Vn/124

7. Galeterone [usan]

8. Tok-001 (galeterone)

9. Vn 124

10. Vn-124-1

11. Wa33e149sw

12. (3s,8r,9s,10r,13s,14s)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol

13. Galeterone (usan)

14. Vn-124

15. 3-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene

16. (3s,8r,9s,10r,13s,14s)-17-(1h-benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol

17. Galeterone [usan:inn]

18. Unii-wa33e149sw

19. (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol

20. Tok-001(galeterone)

21. Tok-001; Galeterone

22. Galeterone [inn]

23. Galeterone [who-dd]

24. Schembl939234

25. Gtpl8638

26. 17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3beta-ol

27. Chembl2105738

28. Galeterone, >=98% (hplc)

29. Chebi:177536

30. (3?)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol

31. 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene

32. Bcpp000040

33. Dtxsid101025602

34. Amy27882

35. Bcp02827

36. Ex-a1025

37. Zinc6718442

38. Bdbm50435990

39. Mfcd16660907

40. Akos005146524

41. Cs-0334

42. Db12415

43. Ac-26549

44. As-56204

45. Hy-70006

46. D10125

47. J-501178

48. Q5518498

49. Vn/124-1;tok-001;vn 124;tok001;tok 001

50. 3beta-hydroxy-17-(1h-benzimidazol-1-yl)-androsta-5,16-diene

51. 3beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene

52. Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-

53. Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3.beta.)-

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₃₂N₂O
Molecular Weight	388.5 g/mol
XLogP3	5.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	1
Exact Mass	388.251463648 g/mol
Monoisotopic Mass	388.251463648 g/mol
Topological Polar Surface Area	38 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	743
Isotope Atom Count	0
Defined Atom Stereocenter Count	6
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

API SUPPLIERS